Copyright(c) 2011 Eisai China lnc.All Rights Reserved.
沪ICP备11005394号-1
沪公网安备31010602001439号
Customer Service Hotline
021-62881220
LINKS
? Record information of Representative
? 已上市替普瑞酮胶囊铬限量检验报告公示说明
News Release
ANTIEPILEPTIC DRUG FYCOMPA? INJECTION FORMULATION LAUNCHED IN JAPAN
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa? (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan.
DISCOVERY RESEARCH ON DUAL OREXIN RECEPTOR ANTAGONIST LEMBOREXANT HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 2024
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that drug discovery research conducted on lemborexant (brand name: Dayvigo?), the dual orexin receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2024 by the PSJ.
EISAI SUBMITS NEW DRUG APPLICATION FOR MECOBALAMIN ULTRAHIGH-DOSE FORMULATION IN JAPAN FOR THE INDICATION OF AMYOTROPHIC LATERAL SCLEROSIS
Eisai Co., Ltd. announced on Jan 26 that it has submitted a New Drug Applicationfor ultrahigh-dose mecobalamin (development code: E0302) for the indication of amyotrophic lateral sclerosis (ALS) to the Pharmaceuticals and Medical Devices Agency in Japan.
EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE EIGHTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY
EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT TASURGRATINIB FOR BILIARY TRACT CANCER WITH FGFR2 GENE FUSION
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has submitted a marketing authorization application in Japan for its in-house discovered fibroblast growth factor (FGF) receptor (FGFR1, FGFR2, FGFR3) selective tyrosine kinase inhibitor tasurgratinib succinate (generic name, development code: E7090, “tasurgratinib”) for biliary tract cancer with?FGFR2?gene fusion. In Japan, tasurgratinib has received orphan drug designation for a prospective indication for unresectable biliary tract cancer with?FGFR2?gene fusion by the Ministry of Health, Labour and Welfare, (MHLW). Under this system, this application will be subject to priority review.
“LEQEMBI? Intravenous Infusion” (Lecanemab) for the Treatment of Alzheimer’s Disease to be Launched in Japan on December 20
TOKYO and CAMBRIDGE, Mass., December 13, 2023?–?Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI??Intravenous Infusion” (200 mg, 500mg, lecanemab) will be launched in Japan on December 20, following its scheduled inclusion in the price listing on the Japan National Health Insurance (NHI) Drug Price List.
